107 Stock Overview
Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Bioasis Technologies Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.008 |
| 52 Week High | CA$0.02 |
| 52 Week Low | CA$0.0005 |
| Beta | 0.46 |
| 1 Month Change | 128.57% |
| 3 Month Change | 1,500.00% |
| 1 Year Change | 45.45% |
| 3 Year Change | -96.88% |
| 5 Year Change | -96.43% |
| Change since IPO | -98.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| 107 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.2% | -1.3% |
| 1Y | 45.5% | 38.4% | 4.2% |
Return vs Industry: 107 exceeded the German Biotechs industry which returned 38.7% over the past year.
Return vs Market: 107 exceeded the German Market which returned 5.5% over the past year.
Price Volatility
| 107 volatility | |
|---|---|
| 107 Average Weekly Movement | 1,028.5% |
| Biotechs Industry Average Movement | 5.4% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 9.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 107's share price has been volatile over the past 3 months.
Volatility Over Time: 107's weekly volatility has increased from 935% to 1028% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | n/a | Deborah Rathjen | https://www.bioasis.us |
Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company’s in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007).
Bioasis Technologies Inc. Fundamentals Summary
| 107 fundamental statistics | |
|---|---|
| Market cap | €269.63k |
| Earnings (TTM) | -€1.95m |
| Revenue (TTM) | €182.92k |
1.5x
P/S Ratio-0.1x
P/E RatioIs 107 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 107 income statement (TTM) | |
|---|---|
| Revenue | CA$269.38k |
| Cost of Revenue | CA$968.85k |
| Gross Profit | -CA$699.47k |
| Other Expenses | CA$2.18m |
| Earnings | -CA$2.88m |
Last Reported Earnings
Nov 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.036 |
| Gross Margin | -259.66% |
| Net Profit Margin | -1,067.59% |
| Debt/Equity Ratio | -82.1% |
How did 107 perform over the long term?
See historical performance and comparison